Urological endoscopes are long, tube-like instruments used in a number of urological procedures to examine inside the body or perform minimally invasive surgery. Urological endoscopes include cystoscopes for endoscopy of the urinary bladder, ureteroscopes for examining the ureter, resectoscopes used in transurethral resection of the prostate (TURP) and nephroscopes used to examine the kidneys.
Female urinary incontinence affects approximately 10% of the population at some point in their lives. Urinary incontinence affects both women and men; however, there is a greater prevalence of incontinence amongst women. The difference is often attributed to changes that occur during pregnancy and childbirth as well as additional factors such as menopause. There are four main categories recognized for urinary incontinence, with 50% of cases diagnosed as stress urinary incontinence (SUI). Surgical treatment using a urinary incontinence sling is one of the most recommended options to help SUI patients become incontinence-free.
The European urology market includes the segments for TURP devices, laser BPH devices, brachytherapy, urinary catheters, nephrostomy devices, urinary incontinence slings, stone treatment devices, urological endoscopes and erectile dysfunction devices. As a whole the urological device market is very well established. This limits potential for substantial growth. Although companies continue to provide novel adaptations to their products, the general trend within the market is a slightly declining ASP. However, some segments are an exception to this lasers (for both BPH and stone management) have recently seen some exciting developments.
The urological endoscope market is comprised of rigid and flexible cystoscopes, semi-rigid and flexible ureteroscopes, rigid resectoscopes and rigid nephroscopes. This report includes the sale of new endoscopes as well as refurbished or repaired units. The refurbished endoscope market in this report refers to units that undergo maintenance or repair and includes repairs made by third-party re-processors.
Erectile dysfunction (ED) can be described as the frequent inability for a man to attain and sustain an erection; this could inhibit sexual intercourse and affect quality of life. Onset of ED can begin at the age of 40 and affects 18 to 30 million men. Occasional failure to achieve an erection is not uncommon but a prevalence of 50% or more of the time could be an indication that treatment is required. ED tends to increase with age but treatment can be sought at any age.
Percutaneous nephrostomy (PCN) procedures create drainage of urine from the upper part of the urinary system to an external urinary collection bag. This is accomplished by puncturing the skin and inserting a catheter, also known as a nephrostomy drainage tube, into the renal pelvis. Under normal circumstances, urine travels between the kidneys and bladder through the ureters. When a blockage prevents this flow, ureteral stents are usually threaded into the ureter as a solution. In cases where this is not the best option, a nephrostomy tube can be used to maintain a passageway between the skin and renal pelvis to facilitate drainage. Without treatment, pressure would build within the urinary system and cause kidney damage. Blockage can result from tumors, kidney stones and pyonephrosis or the infection of the renal pelvis and collecting system.
Internal radiation therapy (RTi), also known as brachytherapy, is a form or RT that puts the radioactive material inside the patient either via a catheter or a needle. In terms of its placement, RTi may be administered as intracavitary or interstitial. In the case of intracavitary, the radioactive material is placed inside a cavity in the body such as in the rectum or uterus; in the case of interstitial, the radioactive material is placed on/near the cancer but not inside a body cavity. The most common form of brachytherapy involves the placement of seeds inside the body involving differing durations and radioactivity. Each seed is approximately the size and shape of a small grain of rice.
This report suite defines intracorporeal non-lithotripsy procedures as endoscopic removal of stones without fragmenting them first with ISWL. These procedures use retrieval devices such as alligator forceps or grasping forceps to crush the stone and remove the fragments or remove the stones whole. In addition, stone retrieval devices can be used to clinch the stone while treatment is being applied. The size, shape and location of the stone as well as the lithotripter being used are the primary determinants of which devices will be used. Stone retrieval devices can be segmented into two varieties based on their material. In the past, stainless-steel stone removal baskets were the standard. However, the emergence of the nitinol basket has shifted the market despite the cost premium.
Urodynamic equipment is used to assess and diagnose urinary voiding dysfunction, typically incontinence and pelvic floor troubles, and is considered the leading procedure for quantitative evaluation. Urodynamic tests are performed using physical measurements, such as urine pressure and flow rate, as well as clinical assessment. The majority are non-invasive tests that are performed in an outpatient setting.
The procedures covered in this report suite includes urinary incontinence, stone management, benign prostate hyperplasia (BPH), prostate cancer treatment, urodynamic testing, nephrostomy and erectile dysfunction management procedures. Each category is further segmented into more specific procedure types.
This report analyzes the markets for the treatment of benign prostate hyperplasia (BPH), prostate cancer, urinary incontinence as well as urinary and kidney stones. Other markets analyzed include urodynamic equipment and urological endoscopes. In 2012, the prostate cancer treatment device market was the second largest segment in the total Indian market for urological devices, almost doubling the stone treatment market. Procedural volume growth in the prostate cancer treatment device market is expected to increase over the 2012 to 2019 forecast period due to the expected rise in the aging population as well as increases in early diagnosis.